The indirect costs of ischemic heart disease through lost productive life years for Australia from 2015 to 2030: results from a microsimulation model.


Journal

BMC public health
ISSN: 1471-2458
Titre abrégé: BMC Public Health
Pays: England
ID NLM: 100968562

Informations de publication

Date de publication:
21 Jun 2019
Historique:
received: 15 07 2018
accepted: 31 05 2019
entrez: 23 6 2019
pubmed: 23 6 2019
medline: 7 9 2019
Statut: epublish

Résumé

Most studies measure the impact of ischemic heart disease (IHD) on individuals using quality of life metrics such as disability-adjusted life-years (DALYs); however, IHD also has an enormous impact on productive life years (PLYs). The objective of this study was to project the indirect costs of IHD resulting from lost PLYs to older Australian workers (45-64 years), government, and society 2015-2030. Nationally representative data from the Surveys of Disability, Ageing and Carers (2003, 2009) were used to develop the base population in the microsimulation model (Health&WealthMOD2030), which integrated data from established microsimulation models (STINMOD, APPSIM), Treasury's population and workforce projections, and chronic conditions trends. We projected that 6700 people aged 45-64 were out of the labour force due to IHD in 2015, increasing to 8100 in 2030 (21 increase). National costs consisted of a loss of AU$273 (US$263) million in income for people with IHD in 2015, increasing to AU$443 ($US426) million (62% increase). For the government, extra welfare payments increased from AU$106 (US$102) million in 2015 to AU$143 (US$138) million in 2030 (35% increase); and lost income tax revenue increased from AU$74 (US$71) million in 2015 to AU$117 (US$113) million in 2030 (58% increase). A loss of AU$785 (US$755) million in GDP was projected for 2015, increasing to AU$1125 (US$1082) million in 2030. Significant costs of IHD through lost productivity are incurred by individuals, the government, and society. The benefits of IHD interventions include not only improved health but also potentially economic benefits as workforce capacity.

Sections du résumé

BACKGROUND BACKGROUND
Most studies measure the impact of ischemic heart disease (IHD) on individuals using quality of life metrics such as disability-adjusted life-years (DALYs); however, IHD also has an enormous impact on productive life years (PLYs). The objective of this study was to project the indirect costs of IHD resulting from lost PLYs to older Australian workers (45-64 years), government, and society 2015-2030.
METHODS METHODS
Nationally representative data from the Surveys of Disability, Ageing and Carers (2003, 2009) were used to develop the base population in the microsimulation model (Health&WealthMOD2030), which integrated data from established microsimulation models (STINMOD, APPSIM), Treasury's population and workforce projections, and chronic conditions trends.
RESULTS RESULTS
We projected that 6700 people aged 45-64 were out of the labour force due to IHD in 2015, increasing to 8100 in 2030 (21 increase). National costs consisted of a loss of AU$273 (US$263) million in income for people with IHD in 2015, increasing to AU$443 ($US426) million (62% increase). For the government, extra welfare payments increased from AU$106 (US$102) million in 2015 to AU$143 (US$138) million in 2030 (35% increase); and lost income tax revenue increased from AU$74 (US$71) million in 2015 to AU$117 (US$113) million in 2030 (58% increase). A loss of AU$785 (US$755) million in GDP was projected for 2015, increasing to AU$1125 (US$1082) million in 2030.
CONCLUSIONS CONCLUSIONS
Significant costs of IHD through lost productivity are incurred by individuals, the government, and society. The benefits of IHD interventions include not only improved health but also potentially economic benefits as workforce capacity.

Identifiants

pubmed: 31226965
doi: 10.1186/s12889-019-7086-5
pii: 10.1186/s12889-019-7086-5
pmc: PMC6588908
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

802

Subventions

Organisme : Australian Research Council
ID : LP100100158
Organisme : National Health and Medical Research Council of Australia and the Sydney Medical Foundation
ID : NA

Références

Am J Manag Care. 2001 Jan;7(1):27-34
pubmed: 11209448
Arch Intern Med. 2003 Feb 10;163(3):333-9
pubmed: 12578514
Health Econ. 2006 Mar;15(3):241-61
pubmed: 16229055
Eur Heart J. 2006 Jul;27(13):1610-9
pubmed: 16495286
Prev Med. 2008 Jan;46(1):9-13
pubmed: 17475317
Med J Aust. 2008 Jan 7;188(1):36-40
pubmed: 18205562
Cochrane Database Syst Rev. 2010 Mar 17;(3):CD006772
pubmed: 20238349
Int J Epidemiol. 1991 Mar;20(1):239-45
pubmed: 2066228
Int J Cardiol. 2011 Jan 7;146(1):125-6
pubmed: 20965596
Int J Cardiol. 2012 Mar 22;155(3):406-8
pubmed: 21094552
Circulation. 2011 Mar 1;123(8):933-44
pubmed: 21262990
Eur Heart J. 2012 Jul;33(14):1769-76
pubmed: 22296945
BMJ Open. 2013 May 28;3(5):null
pubmed: 23793652
Circulation. 2014 Apr 8;129(14):1493-501
pubmed: 24573351
Circulation. 2014 Jun 17;129(24):2528-38
pubmed: 24727094
Eur J Cardiovasc Nurs. 2016 Apr;15(3):e27-36
pubmed: 25648847
Psychol Health Med. 2015;20(5):582-93
pubmed: 25652183
Med J Aust. 2015 Sep 21;203(6):260.e1-6
pubmed: 26377293
Circulation. 2016 Feb 23;133(8):742-55
pubmed: 26903017
Circulation. 2016 Mar 29;133(13):1302-31
pubmed: 26927362
PLoS One. 2016 Apr 13;11(4):e0151460
pubmed: 27073855
Circulation. 2016 Oct 4;134(14):999-1009
pubmed: 27507406
JAMA. 2016 Sep 13;316(10):1049-50
pubmed: 27623460
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Circulation. 2016 Oct 4;134(14):1010-1012
pubmed: 27698049

Auteurs

Deborah Schofield (D)

Department of Economics, Faculty of Business and Economics, Centre for Economic Impacts of Genomic Medicine (GenIMPACT), Macquarie University, Sydney, NSW, 2109, Australia.

Michelle Cunich (M)

The Boden Institute of Obesity, Nutrition, Exercise & Eating Disorders, Charles Perkins Centre, The University of Sydney, and Sydney Health Economics, Sydney Local Health District, John Hopkins Drive, Camperdown, NSW, 2006, Australia. michelle.cunich@sydney.edu.au.

Rupendra Shrestha (R)

Department of Economics, Faculty of Business and Economics, Centre for Economic Impacts of Genomic Medicine (GenIMPACT), Macquarie University, Sydney, NSW, 2109, Australia.
Faculty of Pharmacy, The University of Sydney, Sydney, NSW, 2006, Australia.

Megan Passey (M)

University Centre for Rural Health, School of Public Health, The University of Sydney, Lismore, NSW, 2480, Australia.

Lennert Veerman (L)

Cancer Council NSW, 153 Dowling Street, Woolloomooloo, NSW, 2011, Australia.
Griffith University, School of Medicine, Gold Coast campus, Southport, QLD, 4222, Australia.

Robert Tanton (R)

National Centre for Social and Economic Modelling, University of Canberra, Canberra, ACT, Australia.

Simon Kelly (S)

National Centre for Social and Economic Modelling, University of Canberra, Canberra, ACT, Australia.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH